

Date: 27th September, 2024

To,
The Manager,
Department of Corporate Services,
BSE Limited
P. J. Towers, Dalal Street,
Fort, Mumbai – 400 001
Scrip Code:533573

To,
The Manager,
Listing Department,
National Stock Exchange of India Ltd.
'Exchange Plaza', Bandra Kurla Complex,
Bandra (E), Mumbai – 400 051
NSE Symbol: APL LTD

Dear Sir/Madam,

Sub: Alembic Pharmaceuticals Limited received an Establishment Inspection Report (EIR) for its Oral Solid Formulation Facility(F-1) at Panelav.

Ref.: Our earlier intimation dated 26th July, 2024 - US FDA inspection at Alembic Pharmaceuticals Limited' Oral Solid Formulation Facility (F-I) at Panelav.

We are pleased to inform the exchanges that the Company has received an Establishment Inspection Report (EIR) from the US Food and Drug Administration (US FDA) for the inspection carried out by them at our Oral Solid Formulation Facility (F-I) from 17th July, 2024 to 26th July, 2024.

With this, for all our USFDA facilities, EIRs are in place.

We request you to kindly take the same on record.

Thanking you,

Yours faithfully,

For Alembic Pharmaceuticals Limited

Manisha Saraf
Company Secretary

ALEMBIC PHARMACEUTICALS LIMITED

REGD. OFFICE: ALEMBIC ROAD, VADODARA - 390 003. • TEL: (0265) 2280550, 2280880 • FAX: (0265) 2281229
Website : www.alembicpharmaceuticals.com • E-mail : alembic@alembic.co.in • CIN : L24230GJ2010PLC061123